Lomustine
Pronunciation: /ˈloʊmʌstiːn/
Also written as: CCNU — 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea
An alkylating chemotherapy agent used in brain tumor treatment, particularly for recurrent gliomas and medulloepitheliomas.
Full Definition
Lomustine (CCNU) is an oral alkylating chemotherapy agent belonging to the nitrosourea class of drugs, commonly used in the treatment of brain tumors. It crosses the blood-brain barrier effectively, making it particularly valuable in neurosurgical oncology. Lomustine is often used as a single agent or in combination regimens for recurrent glioblastoma, anaplastic gliomas, and certain pediatric brain tumors. The drug causes DNA cross-linking and has a delayed myelosuppressive effect, requiring careful monitoring of blood counts. Treatment cycles are typically spaced 6-8 weeks apart due to its prolonged bone marrow suppression.
Usage
Usage note: Also known by the acronym CCNU; monitor for delayed hematologic toxicity.
In Context
- "The patient with recurrent glioblastoma was started on lomustine 130 mg/m² every 6 weeks." — Chemotherapy protocol
- "Lomustine-induced thrombocytopenia required dose reduction in the subsequent cycle." — Toxicity management note